Merck and AmoyDx to jointly introduce liquid biopsy RAS biomarker test in China

Merck has entered into an agreement with Amoy Diagnostics (AmoyDx) to develop and commercialise the new ADx-SuperARMS liquid biopsy RAS test for metastatic colorectal cancer (mCRC).

Free Report

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.

By GlobalData

By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The test will be developed based on AmoyDx real-time polymerase chain reaction (PCR) technology, AmoyDx-Super-Amplification-Refractory Mutation System (ADx-SuperARMS).

ADx-SuperARMS has been approved by the Consensus Group for KRAS Gene Mutation Detection in Colorectal Carcinoma, part of the China Pathology Quality Control Centre.

"Our collaboration with AmoyDx will support our goal of improving care for patients with metastatic colorectal cancer, by providing access to state-of-the-art, reliable and accurate testing technology."

It is a mutation detection technology which identifies mutations in blood samples containing a low 0.2% mutant DNA in the presence of wild-type genomic DNA.

The liquid biopsy test is easy to use and is expected to provide clinical practices with accurate molecular diagnostic screening.

It features cards pre-loaded with polymerase chain reaction (PCR) which facilitates a faster and sensitive mode of operation.

Merck biopharma business Chief Marketing and Strategy Officer Rehan Verjee said: “It is now well accepted within the oncology community that understanding the individual RAS biomarker status of metastatic colorectal cancer patients is key to supporting timely treatment decision-making, and results of the recent TAILOR study in China further support the efficacy of targeted therapies such as cetuximab in RAS wild-type patients.

“China is a key market for us, and our collaboration with AmoyDx will support our goal of improving care for patients with metastatic colorectal cancer, by providing access to state-of-the-art, reliable and accurate testing technology to enable a higher standard of care in China.”

Merck and AmoyDx are planning to introduce the ADx-SuperARMS liquid biopsy RAS test in Chinese medical centres next year.

The test will initially be available for research use only (RUO) while AmoyDx apply for the CE Mark Approval of the test this year.